With COVID-19, people with diabetes face the added risk of poorer outcomes if infected, creating an even greater urgency to ensure proper management of overall health and chronic conditions.

As a nation we've reached a tipping point as to what patients can bear when it comes to the price of insulin, a drug used to control blood sugar levels for people with insulin-dependent diabetes. Millions of people who need this life-saving medication face affordability barriers in the form of rising insulin prices and out-of-pocket costs.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Cost-Containment